Secondary bacterial infections and co-infections frequently affect COVID-19 patients. However, bacterial coinfection rates increase in patients admitted in the Intensive Care Units (ICUs), and those diseases can be due to superinfections by Multidrug-Resistant (MDR) bacteria. Most of these infections are related to high-risk carbapenemase-producing clones and occasionally with resistance to new β-lactam-β-lactamase inhibitor combinations. This highlights the urgency to revise frequent and empiric prescription of broad-spectrum antibiotics in COVID-19 patients, with more attention to evidence-based studies and the need to maintain antimicrobial stewardship and infection control programs in pandemic crises. Additionally, the SARS-CoV-2 pandemic highlighted the challenge that an emerging pathogen provides in adapting prevention measures regarding both the risk of exposure to caregivers and the need to maintain quality of care
